SureTrader SureTrader
Home > Boards > Canadian > Biotechs >

Trillium Therapeutics Inc. (TRIL)

TRIL RSS Feed
Add TRIL Price Alert      Hide Sticky   Hide Intro
Moderator: NY1972
Search This Board:
Last Post: 9/27/2016 10:52:17 AM - Followers: 34 - Board type: Free - Posts Today: 1

Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR)

Home: http://trilliumtherapeutics.com/trillium-home/default.aspx

 

Trillium Therapeutics Inc. 
2488 Dunwin Drive 
Mississauga, Ontario, 
Canada L5L 1J9 
Tel: +1 416.595.0627

 

Trillium Therapeutics is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. We have two premier pre-clinical programs, SIRPαFc and a CD200 monoclonal antibody, which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. 

 

SEC filings:  http://www.nasdaq.com/symbol/tril/sec-filings

 

Twitter:  https://twitter.com/search?q=%24TRIL&src=ctag

 

Quote:  https://www.google.com/finance?q=NASDAQ%3ATRIL&ei=dWJkV-kHiKV5wPiX4As

 

Canadian Insider:  https://www.canadianinsider.com/company?menu_tickersearch=tr

 
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Last update 6/17/2016

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TRIL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TRIL News: Report of Foreign Issuer (6-k) 08/31/2016 07:13:52 AM
TRIL News: Report of Foreign Issuer (6-k) 08/23/2016 07:02:06 AM
TRIL News: Report of Foreign Issuer (6-k) 08/17/2016 07:09:10 AM
TRIL News: Report of Foreign Issuer (6-k) 08/12/2016 07:14:55 AM
TRIL News: Report of Foreign Issuer (6-k) 06/07/2016 07:21:19 AM
PostSubject
#352   TTI621 + TTI281 = perfect 1st line combo NY1972 09/27/16 10:52:17 AM
#351   Study demonstrates for the first time in a NY1972 09/26/16 11:01:01 PM
#350   I don't let the overboughtness of the chart stocktrademan 09/23/16 06:24:52 PM
#349   Its approaching overbought. Where to from here? DFRAI 09/23/16 05:48:15 PM
#348   B028 Blockade of the CD47 “Do not eat” NY1972 09/22/16 10:45:16 PM
#347   In my estimation - TRIL should know some DFRAI 09/19/16 12:35:39 PM
#346   47 CEO: NY1972 09/19/16 11:28:06 AM
#345   TRIL bullish 13.30 stocktrademan 09/16/16 12:54:01 PM
#344   Preclinical IT ADU-S100 NY1972 09/09/16 11:47:00 PM
#343   Analysis by Biomaven: NY1972 09/08/16 02:33:42 PM
#342   CD47 expression in gastric cancer, AML (acute myelogenous NY1972 09/07/16 08:25:23 PM
#341   Use of inhibitory antibodies against CD47 offers an NY1972 09/07/16 08:10:32 PM
#340   P1 Intratumoral Injections of TTI-621 in subjects with NY1972 09/07/16 03:13:25 PM
#339   Looking at invivo data, I believe this is NY1972 09/07/16 03:02:34 PM
#338   They changed slide 15 DFRAI 09/06/16 03:17:45 PM
#337   They changed slide 15 DFRAI 09/06/16 03:17:45 PM
#336   Insight info in 8/31 presentation: no anemia?? NY1972 09/06/16 10:33:17 AM
#335   BET protein BRD4 directly regulated expression of the NY1972 09/01/16 08:36:49 PM
#334   To do list: NY1972 09/01/16 08:15:01 PM
#333   Phagocytosis of CD47+ RBCs by LPS-activated SIRPa-/- macrophages. NY1972 08/30/16 11:51:30 PM
#332   epidermal growth factor (EGF) stabilizes PD-L1 NY1972 08/30/16 03:44:27 PM
#331   Oxygen can impair cancer immunotherapy in mice NY1972 08/27/16 06:54:25 PM
#330   "there are other immune targets. Many immune therapies NY1972 08/25/16 11:37:16 PM
#329   TTI621 binds to cancer cells mostly, RBC poorly. NY1972 08/25/16 12:56:09 PM
#328   It all sounds pretty amazing. DFRAI 08/25/16 09:23:49 AM
#327   TAM is a major stromal, metastasis component. Slowing NY1972 08/24/16 10:38:28 AM
#326   I was thinking more along the lines of jondoeuk 08/23/16 11:34:12 PM
#325   TRIL is taking serial, on-treatment tumor biopsies of NY1972 08/23/16 07:00:27 PM
#324   Thanks for this. I wonder why they are jondoeuk 08/23/16 03:37:01 PM
#323   Time to present some in vivo solid tumor data. NY1972 08/23/16 11:31:20 AM
#322   TTI-621 P1 Exclusion Criteria: NY1972 08/22/16 08:46:00 PM
#321   1 MDVN > 100 TRIL NY1972 08/22/16 12:05:45 PM
#320   Fighting cancer like an infection NY1972 08/21/16 12:16:13 PM
#319   From detailed evaluation of serial, on-treatment tumor biopsies NY1972 08/18/16 08:52:40 PM
#318   Skoal tobacco packed in his lip => cancer NY1972 08/18/16 06:03:10 PM
#317   Review Time for initial submission of an Investigational NY1972 08/18/16 12:38:50 PM
#316   Intratumoral injection of SD-101 + ipilimumab + radiation NY1972 08/18/16 10:22:41 AM
#315   Does anyone know when the company put in jondoeuk 08/18/16 10:06:16 AM
#314   Tioma expects to advance its lead candidate to NY1972 08/17/16 10:57:52 PM
#313   Boom Shaka_Zulu 08/17/16 10:54:52 AM
#312   Mycosis Fungoides is the most common form of NY1972 08/17/16 09:42:07 AM
#311   TRILLIUM THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH LongRun8 08/17/16 07:19:30 AM
#310   SP @ $11, EV = 50 mil. for NY1972 08/16/16 12:23:51 PM
#309   Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing NY1972 08/16/16 09:44:35 AM
#308   On watch Shaka_Zulu 08/16/16 12:18:45 AM
#307   TTi-622 for MS? NY1972 08/15/16 08:52:01 PM
#306   From dewophile: NY1972 08/12/16 07:39:41 PM
#305   CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small DFRAI 08/12/16 03:00:51 PM
#304   Notes As of June 30, 2016, Trillium had cash NY1972 08/12/16 12:45:25 PM
#303   6K NY1972 08/12/16 09:49:52 AM
PostSubject